影响激素受体阳性和人表皮生长因子受体 2 阴性乳腺癌患者接受新辅助化疗后病理完全缓解的因素。

Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.

机构信息

Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.

Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

出版信息

Oncology. 2022;100(10):529-535. doi: 10.1159/000526155. Epub 2022 Jul 26.

DOI:10.1159/000526155

PMID:35882211

Abstract

INTRODUCTION

Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is associated with improvement in survival outcomes. This study evaluated the pCR in patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer after NAC.

METHODS

We evaluated 417 patients who were diagnosed with invasive breast cancer and treated with NAC followed by curative surgery between January 2007 and December 2020 and analyzed the pCR for HR-positive and HER2-negative breast cancer.

RESULTS

The median age at the time of surgery was 45.4 years, and 9.1% of patients (38 of 417) with HR-positive/HER2-negative status had pCR. Among patients with HR-positive/HER2-negative breast cancer, patients with single HR-positivity had a 20.2% pCR rate, and patients with double HR-positivity had a 4.4% pCR rate. Patients with a high Ki-67 index exhibited a higher pCR rate than those with a lower Ki-67 index (14.5% vs. 3.2%). Patients with single HR-positive and high Ki-67 values exhibited a significantly higher pCR rate than those with double HR-positive and low Ki-67 values (27.8% vs. 2.1%; p < 0.001).

CONCLUSION

NAC could improve prognosis in patients with HR-positive/HER2-negative breast cancer with a single HR-positive and high Ki-67 values.

摘要

简介

新辅助化疗（NAC）后病理完全缓解（pCR）与生存结局改善相关。本研究评估了 NAC 后激素受体（HR）阳性和人表皮生长因子受体 2（HER2）阴性乳腺癌患者的 pCR。

方法

我们评估了 417 例于 2007 年 1 月至 2020 年 12 月期间因浸润性乳腺癌接受 NAC 治疗后行根治性手术的患者，并分析了 HR 阳性/HER2 阴性乳腺癌的 pCR。

结果

手术时的中位年龄为 45.4 岁，9.1%（38/417）的 HR 阳性/HER2 阴性患者有 pCR。在 HR 阳性/HER2 阴性乳腺癌患者中，单 HR 阳性患者的 pCR 率为 20.2%，双 HR 阳性患者的 pCR 率为 4.4%。Ki-67 指数高的患者 pCR 率高于 Ki-67 指数低的患者（14.5% vs. 3.2%）。单 HR 阳性且 Ki-67 指数高的患者 pCR 率明显高于双 HR 阳性且 Ki-67 指数低的患者（27.8% vs. 2.1%；p<0.001）。